Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
166.86
-0.72 (-0.43%)
4:40:02 PM EDT: $166.80 -0.06 (-0.04%)
Products

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted For TALQUETAMAB

Published: 06/29/2022 12:13 GMT
Johnson & Johnson (JNJ) - Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for the Treatment of Relapsed Or Refractory Multiple Myeloma.
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for Treatment of Relapsed Or Refractory Multiple Myeloma.